A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)
Clinical trial NCT05927571 · RECRUITING
Trial details
- NCT number
- NCT05927571
- Sponsor
- Genentech, Inc.
- Status
- RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2023-08-10
- Primary completion
- 2027-07-31
- Enrollment
- 120
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.